Home - Pharmaceutical Development & Distribution

Advancing neuroscience.
Expanding access.

Rune Healthcare develops differentiated pharmaceutical products and builds international routes to market through focused R&D, licensing, partnering and export operations.

A diversified pharmaceutical model.

Export Operations

Globalising approved and established medicines through international distribution partnerships.

Late-Stage Development

Advancing differentiated products toward approval and launch

Mid-Stage Development

In-licensing and developing promising pharmaceutical opportunities.

Early-Stage Innovation

Creating new formulation and drug-delivery concepts around established medicines.

Press releases and company updates.

Rune Healthcare and BDD enter into a Licence Agreement for the development of Novel Treatments for Psychiatric Disorders

August 27, 2026

This agreement will combine Rune Healthcare’s neuroscience development strategy with BDD’s proprietary OralogiK™ drug-delivery technology to develop four differentiated pharmaceutical products designed to address important needs in the treatment of…

Read Press Release →

RUN-247XR Prototype C Achieves Target Product Profile Parameters

June 1, 2023

Following reformulation, Prototype C achieved its target product profile parameters in vitro and in vivo and was ready to progress toward final clinical development, manufacturing scale-up and commercialisation

Read Press Release →

Rune Healthcare Builds Centralised International Pharmaceutical Export Network

January 1, 2022

Rune expanded partnerships with US pharmaceutical companies, using a centralised hub in Turkey and secondary distribution across Eurasia, Africa and South America.

Read Press Release →

Advancing neuroscience.
Expanding access.

Development and commercialisation working together.

A diversified pharmaceutical model.

Export Operations

Late-Stage Development

Mid-Stage Development

Early-Stage Innovation

Innovation can mean making a proven medicine work better for patients.

Press releases and company updates.

Rune Healthcare and BDD enter into a Licence Agreement for the development of Novel Treatments for Psychiatric Disorders

RUN-247XR Prototype C Achieves Target Product Profile Parameters

Rune Healthcare Builds Centralised International Pharmaceutical Export Network

About Rune Healthcare

Advancing neuroscience.Expanding access.

Development and commercialisation working together.

A diversified pharmaceutical model.

Export Operations

Late-Stage Development

Mid-Stage Development

Early-Stage Innovation

Innovation can mean making a proven medicine work better for patients.

Press releases and company updates.

Rune Healthcare and BDD enter into a Licence Agreement for the development of Novel Treatments for Psychiatric Disorders

RUN-247XR Prototype C Achieves Target Product Profile Parameters

Rune Healthcare Builds Centralised International Pharmaceutical Export Network

About Rune Healthcare

Advancing neuroscience.
Expanding access.